Trials / Terminated
TerminatedNCT00213577
NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder
Evaluation of the Efficacy and Tolerance of 2 Dosages of Type A Botulinic Toxin in Neurogenic Areactive Bladder Resistant to Oral Medical Treatment
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- University Hospital, Rouen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy and tolerance of 2 dosages (750 versus 500 units) of the Dysport type A botulinic toxin for patient suffering from neurogenic urinary incontinence by an overactive bladder and the failure of anticholinergic drugs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | type A botulinum toxin |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2007-09-01
- Completion
- 2007-10-01
- First posted
- 2005-09-21
- Last updated
- 2015-03-24
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00213577. Inclusion in this directory is not an endorsement.